Pelops trial information with words "completed enrollment"

PELOPS: Clinical Trial with Palbociclib for Pre-surgical ILC Patients

Women who have been diagnosed with Stage 1 – 3 invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a clinical trial.  This trial is open to all ER+ and/or PR+ HER2- patients (ductal or lobular), however it is being enriched with lobular breast cancer patients to promote a better understanding of how ILC might respond differently to these therapies.

Materials Available: Boston 2018 ILC Course

Lobular Breast Cancer (ILC) and the Lobular Breast Cancer Alliance (LBCA) will be featured on the final day of Harvard Medical School’s annual comprehensive educational course Breast Cancer: New Horizons, Current Controversies July 12 – 14, 2018 at the Boston Marriott Long Wharf. Advocate Registration to attend the course is open.

Scroll to Top

Join Us

Subscribe for the Latest News & Updates​

  • This field is for validation purposes and should be left unchanged.